| Symbol | CLLS |
|---|---|
| Name | CELLECTIS ROMAINVILLE |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | - |
| Address | 75013 France 8 rue de la Croix Jarry |
| Telephone | +33 (0)1 81 69 16 0 |
| Fax | — |
| — | |
| Website | http://www.cellectis.com |
| Incorporation | FR |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Euronext Paris |
| CIK | 0001627281 |
| Description | Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the bodys immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The companys gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology. Additional info from NASDAQ: |
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
Read moreCema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
Read moreCellectis Reports Full Year 2025 Financial Results and Provides a Business Update
Read moreCellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Read more